Evaluation and Treatment of Rhinosinusitis with Primary Antibody Deficiency in Adults: Evidence-Based Review with Recommendations.

Based on the currently available evidence, PAD can occur in up to 50% of patients with recalcitrant CRS. Despite presence of multiple studies addressing rhinosinusitis and PAD, the level of evidence supporting different treatment options continues to be lacking. Optimal management require multidisciplinary approach through collaboration with clinical immunology. There is need for higher level studies that compare different treatments in patients with PAD and rhinosinusitis. This article is protected by copyright. All rights reserved.